Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

被引：1

作者：

Cavallo, Federica ^{[1
]}

Follows, George A. ^{[2
]}

Goy, Andre ^{[3
]}

Vermaat, Joost ^{[4
]}

Casasnovas, Rene-Olivier ^{[5
]}

Lavee, Orly ^{[6
]}

Maerevoet, Marie ^{[7
]}

Zijlstra, Josee M. ^{[8
]}

Bakhshi, Sameer ^{[9
]}

Bouabdallah, Reda

Choquet, Sylvain ^{[10
,11
]}

Gurion, Ronit ^{[12
]}

Hill, Brian T. ^{[13
]}

Jaeger, Ulrich ^{[14
]}

Sancho, Juan-Manuel ^{[15
]}

Schuster, Michael W. ^{[16
]}

Thieblemont, Catherine ^{[17
,18
]}

De la Cruz, Fatima ^{[19
]}

Egyed, Miklos ^{[20
]}

Mishra, Sourav ^{[21
]}

Offner, Fritz ^{[22
]}

Vassilakopoulos, Theodoros P. ^{[23
]}

Warzocha, Krzysztof ^{[24
]}

McCarthy, Daniel ^{[25
]}

Ma, Xiwen ^{[25
]}

Corona, Kelly ^{[25
]}

Saint-Martin, Jean-Richard ^{[25
]}

Joshi, Anita ^{[25
]}

Shah, Jatin ^{[25
]}

Van den Neste, Eric ^{[26
]}

Canales, Miguel A. ^{[27
]}

Kalakonda, Nagesh ^{[28
]}

机构：

[1] Univ Torino, Div Hematol, AOU Citta Salute & Sci, Turin, Italy

[2] Cambridge Univ Hosp NHS Fdn Trust, UK CLL Forum, Haematol, Cambridge, England

[3] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[4] Leiden Univ Med Ctr, Dept Hematol, Leiden, Netherlands

[5] Univ Dijon, Dept Hematol, CHU Hop Francois Mitterrand, Dijon, France

[6] St Vincents Hosp, Darlinghurst, NSW, Australia

[7] ULB, Inst Jules Bordet, Dpt Hematol, Brussels, Belgium

[8] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

[9] All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, New Delhi, India

[10] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[11] Hosp Pitie Salpetriere, Paris, France

[12] Rabin Med Ctr, Inst Hematol, Davidoff Canc Ctr, Petah Tiqwa, Israel

[13] Cleveland Clin, Cleveland, OH 44106 USA

[14] Med Univ Vienna, Vienna, Austria

[15] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[16] SUNY Stony Brook, Hosp Canc Ctr, Stony Brook, NY USA

[17] Hop St Louis, AP HP, Hemato Oncol, Paris, France

[18] Diderot Univ, Sorbonne Paris Cite, Paris, France

[19] Hosp Univ Virgen del Rocio, Seville, Spain

[20] Mor Kaposi Teaching Hosp, Kaposvar, Hungary

[21] Inst Med Sci & SUM Hosp, Bhubaneswar, Odisha, India

[22] Univ Ziekenhuis Gent, Ghent, Belgium

[23] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Athens, Greece

[24] Inst Haematol & Transfus Med, Clin Haematol, Warsaw, Poland

[25] Karyopharm Therapeut, Newton, MA USA

[26] Clin Univ St Luc, Brussels, Belgium

[27] Hosp Univ La Paz, Madrid, Spain

[28] Univ Liverpool, Liverpool, Merseyside, England

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122900

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5333

引用

页数：6

共 50 条

[21] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish
Kim, Won Seog
Kim, Tae Min
Walewski, Jan
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle
Oh, Sung Yong
Lim, Francesca Lorraine Wei Inng
Carpio, Cecilia
Tan, Tran-Der
Gutierrez, Antonio
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Li, Jingjin
Ufkin, Melanie
Shariff, Saleem
Chi, Lei
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Prince, H. Miles
BLOOD, 2023, 142
[22] Interim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large B-cell lymphoma patients (R/R DLBCL)
Longcor, J.
Oliver, K.
Friend, J.
Callandar, N.
ANNALS OF ONCOLOGY, 2019, 30 : 435 - 435
[23] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
Peters, Anthea
Nowakowski, Grzegorz S.
Dabas, Rosy
Amoloja, Theresa
Xue, Zhenyi
Koch, Caroline
Waltl, Eva E.
Fleury, Isabelle
BLOOD, 2022, 140 : 3811 - 3813
[24] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Awasthi, Rakesh
Tam, Constantine S.
Jaeger, Ulrich
Jaglowski, Samantha
Foley, Stephen Ronan
van Besien, Koen
Wagner-Johnston, Nina D.
Kersten, Maria Jose
Schuster, Stephen J.
Salles, Gilles
Maziarz, Richard T.
Anak, Ozlem
Pacaud, Lida Bubuteishvili
Gazi, Lucien
Waldron, Edward
Hamilton, Jason
Pruteanu, Iulian
Tai, Feng
Mueller, Karen Thudium
Waller, Edmund K.
CANCER RESEARCH, 2018, 78 (13)
[25] Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Westin, Jason
Maris, Michael B.
Jacobson, Caron A.
Patel, Prapti
Lakhani, Nehal
Harb, Wael
Patel-Donnelly, Dipti
McCaul, Kelly
Escobar, Carolina
Klencke, Barbara
Al-Katib, Ayad M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (01): : 52 - 59
[26] Salvage therapy R-DAOx in patients with relapsed or refractory diffuse large B-CELL lymphoma
Mappa, S.
Rigacci, L.
Nassi, L.
Puccini, B.
Alterini, R.
Carrai, V.
Bernardi, F.
Bosi, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 532 - 532
[27] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
Dickinson, Michael
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Trneny, Marek
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Balari, Anna Sureda
Perez-Callejo, David
Lundberg, Linda
Relf, James
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] Safety and Efficacy of Tisagenlecleucel Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and No Evidence of Active Disease Following Bridging Chemotherapy in the JULIET Trial
Bishop, Michael R.
Maziarz, Richard Thomas T.
Waller, Edmund K.
del Corral, Christopher
Tiwari, Ranjan
Anak, Ozlem
Awasthi, Rakesh
Romanov, Vadim V.
Schuster, Stephen J.
BLOOD, 2018, 132
[29] Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Marie Maerevoet
Josee M. Zijlstra
George Follows
Rene-Olivier Casasnovas
J. S. P. Vermaat
Nagesh Kalakonda
Andre Goy
Sylvain Choquet
Eric Van Den Neste
Brian Hill
Catherine Thieblemont
Federica Cavallo
Fatima De la Cruz
John Kuruvilla
Nada Hamad
Ulrich Jaeger
Paolo Caimi
Ronit Gurion
Krzysztof Warzocha
Sameer Bakhshi
Juan-Manuel Sancho
Michael Schuster
Miklos Egyed
Fritz Offner
Theodoros P. Vassilakopoulos
Priyanka Samal
Matthew Ku
Xiwen Ma
Kelly Corona
Kamal Chamoun
Jatin Shah
Sharon Shacham
Michael G. Kauffman
Miguel Canales
Journal of Hematology & Oncology, 14
[30] Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Maerevoet, Marie
Zijlstra, Josee M.
Follows, George
Casasnovas, Rene-Olivier
Vermaat, J. S. P.
Kalakonda, Nagesh
Goy, Andre
Choquet, Sylvain
Van den Neste, Eric
Hill, Brian
Thieblemont, Catherine
Cavallo, Federica
De la Cruz, Fatima
Kuruvilla, John
Hamad, Nada
Jaeger, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan-Manuel
Schuster, Michael
Egyed, Miklos
Offner, Fritz
Vassilakopoulos, Theodoros P.
Samal, Priyanka
Ku, Matthew
Ma, Xiwen
Corona, Kelly
Chamoun, Kamal
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Canales, Miguel
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)

← 1 2 3 4 5 →